Litigation Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)
✉ Email this page to a colleague
PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)
| Docket | ⤷ Subscribe | Date Filed | 2017-08-14 |
| Court | District Court, D. New Jersey | Date Terminated | 2020-12-18 |
| Cause | 18:1836(b) Civil Action to Protect Trade Secrets | Assigned To | Brian R. Martinotti |
| Jury Demand | Plaintiff | Referred To | Douglas Arpert |
| Patents | 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-02-08 | 136 | are: (1) U.S. Patent No. 9,375,478; (2) U.S. Patent No. 9,687,526; (3) U.S. Patent No. 9,744,239; (4) …any of five patents Par purports to own in connection with Vasostrict®. 5 5 The patents at issue are…) U.S. Patent No. 9,744,209; and (5) U.S. Patent No. 9,750,785. | External link to document | |
| 2018-06-18 | 249 | Brief | are listed below: • U.S. Patent No. 9,375,478 (“the ’478 patent”), which issued on June 28, …and Par itself. By definition, Par’s own patents 1 and patent applications covering its product are the… at least five patents relating to its vasopressin injection product. These patents, with their corresponding…previously published; • U.S. Patent No. 9,687,526 (“the ’526 patent”), which issued on June 27, …February 9, 2017; • U.S. Patent No. 9,744,239 (“the ’239 patent”), which issued on August 29, | External link to document |
| 2018-06-18 | 251 | Brief | consist of information in Par’s own patent and published patent application, as well general knowledge…published U.S. Patent Application No. 2017/0290881 (the “’881 publication”), Par’s U.S. Patent No. 9,375,478…which is disclosed in an issued patent or in a published patent application, is not secret and thus…9,375,478 (the “’478 patent”), and other public information disclose a majority of Par’s vasopressin …regarding vasopressin, and possibly to later bring patent litigation against QuVa. (Ex. 349 at 2-3, 19 | External link to document |
| 2018-06-18 | 252 | Brief | 219 is a true and correct copy of U.S. Patent 9,375,478 to Kenney et al., as produced as QuVa007870…Hinchen 11-10-2017 219 U. S. Patent 9,375,478 Kenney et al. 06-28-2016…as Exhibit 210 is a true and correct copy of US Patent Application Publication 2017/0290881 A1 (Kannan… QuVa007762 210 US Patent Application Publication 2017/0290881 A1 10-12 | External link to document |
| 2018-06-18 | 255 | Brief | public, for example in Par’s U.S. Patent No. 9,375,478 (“the ‘478 patent”), the USP monographs for vasopressin…reviewed reference materials and Par patents and published patent applications relating to vasopressin…readily available to the public in Par’s patent and published patent applications, as well as other references… Par’s HPLC analytical methods, patents, and published patent applications, are coated with chemical…method of Example 1 of the ‘478 patent. Specifically, the ‘478 patent in Example 1 states that “[ | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
